Featured Research

from universities, journals, and other organizations

Experimental drug raises 'good' cholesterol, may help control diabetes

July 20, 2011
American Heart Association
An experimental cholesterol drug improved blood sugar control in diabetic patients on statins, a new study shows. The drug raises levels of "good" cholesterol and may help lower cardiovascular disease risk in people with diabetes.

A medicine designed to improve levels of "good" cholesterol may also help control blood sugar in people with diabetes who are taking cholesterol-lowering drugs, according to a new analysis in Circulation: Journal of the American Heart Association.

Researchers made the finding while analyzing data from a clinical trial on the drug torcetrapib that was halted five years ago. Torcetrapib is a cholesterol ester transfer protein (CETP) inhibitor, a type of drug that increases levels of high-density lipoproteins (HDLs, or "good" cholesterol).

The study found that 6,661 people with type 2 diabetes -- also known as "adult-onset" diabetes -- showed improved blood sugar control when taking torcetrapib along with a statin medication that reduces low-density lipoproteins (LDLs or "bad" cholesterol). Subjects who took a statin and a placebo did not see such improvements.

"The possibility that CETP inhibitor drugs may not only reduce the risk of heart attack and stroke, but may also improve the control of blood sugar in people with diabetes, is an exciting prospect that may translate into real health benefits for people with diabetes," said the study's lead author, Philip Barter, M.B.B.S., Ph.D., a professor of medicine and director of the Heart Research Institute at the University of Sydney in Australia.

About 220 million people worldwide have diabetes, according the World Health Organization. An estimated 90 percent to 95 percent of them have type 2 diabetes, which increases the risk for heart disease, stroke and various other health problems.

While the experimental drug was not as effective in taming diabetes as drugs that are commonly used for that purpose, it did reduce the adverse impact on blood sugar commonly seen with statin use, Barter said. "Inhibition of CETP has the potential to prevent a worsening of diabetic control that often occurs in people taking statin drugs," he said.

The clinical trial called ILLUMINATE (Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events) involved more than 15,000 people ages 45 to 75. They all had a history of heart attack, stroke, chest pain, peripheral vascular disease or cardiac revascularization (angioplasty or bypass). All were taking medicine to help control their diabetes. The trial was stopped prematurely in 2006 when patients receiving torcetrapib and a statin called atorvastatin had more cardiovascular problems and deaths than those given atorvastatin and a placebo. Researchers later determined those problems were due to other effects of the drug, not its CETP inhibition.

While the development of torcetrapib was halted, two other CETP inhibitors that scientists say do not cause the adverse effects -- dalcetrapib and anacetrapib -- are in the government's drug approval pipeline.

The analysis of the ILLUMINATE data found:

  • After three months of treatment, those given both drugs had fasting blood sugar 0.34 millimoles per liter lower than in the group receiving just the statin.
  • Fasting insulin was 11.7 microunits per milliter lower in the group receiving both drugs, and insulin resistance was also improved.
  • After six months, average levels of blood sugar control over a months-long period were lower in the group receiving both drugs (7.06 percent) versus the group receiving just the statin (7.29 percent).

Use of the CETP inhibitor also improved glucose and insulin measurements in study participants without diabetes, although not as much. In addition, the study found that HDL levels had risen 66.8 percent after a year of taking torcetrapib and the statin, compared with minimal change in the other group. It's unclear whether torcetrapib's impact on HDL may account in part for the improvement in diabetic control, the scientists noted.

A key strength of the study, Barter said, is the size of ILLUMINATE. Yet scientists must determine whether the blood sugar effects were due to the drug's CETP inhibition or some other mechanism -- an issue that current trials with dalcetrapib and anacetrapib should help clarify, Barter said.

The Heart Research Institute in Sydney funded the study. Pfizer Inc. provided statistical assistance.

Coauthors are Kerry-Anne Rye, Ph.D.; Jean-Claude Tardif, M.D.; David D. Waters, M.D.; S. Matthijs Boekholdt, M.D., Ph.D.; Andrei Breazna, Ph.D.; and John J.P. Kastelein, M.D., Ph.D. Author disclosures and sources of funding are on the manuscript.

Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.

Journal Reference:

  1. Philip J. Barter, Kerry-Anne Rye, Jean-Claude Tardif, David D. Waters, S. Matthijs Boekholdt, Andrei Breazna, John J.P. Kastelein. Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial. Circulation, 2011; DOI: 10.1161/CIRCULATIONAHA.111.018259

Cite This Page:

American Heart Association. "Experimental drug raises 'good' cholesterol, may help control diabetes." ScienceDaily. ScienceDaily, 20 July 2011. <www.sciencedaily.com/releases/2011/07/110718161328.htm>.
American Heart Association. (2011, July 20). Experimental drug raises 'good' cholesterol, may help control diabetes. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2011/07/110718161328.htm
American Heart Association. "Experimental drug raises 'good' cholesterol, may help control diabetes." ScienceDaily. www.sciencedaily.com/releases/2011/07/110718161328.htm (accessed October 21, 2014).

Share This

More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations

Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
CDC Calls for New Ebola Safety Guidelines

CDC Calls for New Ebola Safety Guidelines

AP (Oct. 20, 2014) Centers for Disease Control and Prevention Director Dr. Tom Frieden laid out new guidelines for health care workers when dealing with the deadly Ebola virus including new precautions when taking off personal protective equipment. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.


Breaking News:

Strange & Offbeat Stories

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News


Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile

Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins